Review: Prodrug Concept in Drug Design

Nada Abdelnasser Elsharif

Abstract


        

 

Abstract

In the world of drug discovery and development, prodrugs have become a powerful method for improving biopharmaceutical, physicochemical or pharmacokinetic properties of pharmacologically active agents. The purpose of this review is to provide some types of prodrugs which are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. The target of prodrug design is to beat the undesirable drug properties, such as low target selectivity, low solubility in water or lipid membranes, chemical instability, irritation or pain after local administration, presystemic toxicity and metabolism. In this article, we focused on to describe the basic functional groups that are amenable to prodrug design and highlight the major applications of the prodrug strategy. Furthermore, the concepts of prodrug and the classifications of prodrugs will be offered in this article.

 

Keywords: Prodrug,derivatives of drug, drug-promoiety,antiviral, anticancer

 


Full Text:

PDF

References


Albert, A. (1958). Chemical Aspects of Selective Toxicity. Nature, 182(4633), 421-423.

Huttunen, K. M., Raunio, H., & Rautio, J. (2011). Prodrugs--from Serendipity to Rational Design. Pharmacological Reviews, 63(3), 750-771.

Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006). Paracetamol: New Vistas of an Old Drug. CNS Drug Reviews, 12(3-4), 250-275.

Stella, V. J., Borchardt, R. T., Hageman, M. J., Maag, H., Oliyai, R., & Tilley, J. W. (2007). Prodrugs Challenges and Rewards Part 1. New York (NY): Springer.

Wermuth, C. G. (2003). The practice of medicinal chemistry. Amsterdam: Academic Press.

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008). Prodrugs: Design and clinical applications. Nature Reviews Drug Discovery, 7(3), 255-270.

Jana, S., Mandlekar, S., & Marathe, P. (2010). Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists. CMC Current Medicinal Chemistry, 17(32), 3874-3908.

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008). Prodrugs: Design and clinical applications. Nature Reviews Drug Discovery, 7(3), 255-270.

Mahato, R., Tai, W., & Cheng, K. (2011). Prodrugs for improving tumor targetability and efficiency. Advanced Drug Delivery Reviews, 63(8), 659-670.

Huttunen, K. M., Raunio, H., & Rautio, J. (2011). Prodrugs--from Serendipity to Rational Design. Pharmacological Reviews, 63(3), 750-771.

Han, H., & Amidon, G. L. (2000). Targeted prodrug design to optimize drug delivery. AAPS PharmSci, 2(1), 48-58.

Williams, R. O., Taft, D. R., & McConville, J. T. (2008). Advanced drug formulation design to optimize therapeutic outcomes. New York: Informa Healthcare.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Research and Reviews: A Journal of Pharmaceutical Science